In the clinic, this strategy has already proven to be successful for some patients with BRAFV600‐mutant metastatic melanoma as therapy combining a MEK1/2 inhibitor with a BRAFV600E inhibitor was successfully applied [85]. This evidence concerns the gene MAP2K1 and metastatic melanoma.